Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke

Giuseppe Licata; Antonino Tuttolomondo; Domenico Di Raimondo; Salvatore Corrao; Riccardo Di Sciacca; Antonio Pinto

doi:10.1160/TH08-06-0375

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 101(05): 929-937
DOI: 10.1160/TH08-06-0375

Wound Healing and Inflammation/Infection

Schattauer GmbH

Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke

Authors

Giuseppe Licata^*
Antonino Tuttolomondo^*
Domenico Di Raimondo

¹Dipartimento Biomedico di Medicina Interna e Specialistica, Università degli Studi di Palermo
Salvatore Corrao

¹Dipartimento Biomedico di Medicina Interna e Specialistica, Università degli Studi di Palermo
Riccardo Di Sciacca

¹Dipartimento Biomedico di Medicina Interna e Specialistica, Università degli Studi di Palermo
Antonio Pinto

¹Dipartimento Biomedico di Medicina Interna e Specialistica, Università degli Studi di Palermo

Abstract

Summary

Few studies have examined the relationship between inflammatory biomarker blood levels, cardioembolic stroke subtype and neurological deficit. So the aim of our study is to evaluate plasma levels of immuno-inflammatory variables in patients with cardio-embolic acute ischaemic stroke compared to other diagnostic subtypes and to evaluate the relationship between immuno-inflammatory variables, acute neurological deficit and brain infarct volume. One hundred twenty patients with acute ischaemic stroke and 123 controls without a diagnosis of acute ischaemic stroke were evaluated. The type of acute ischaemic stroke was classified according to the TOAST classification. We evaluated plasma levels of IL-1β, TNF-α, IL-6 and IL-10, E-selectin, P-selectin, sICAM-1,sVCAM-1, vWF, TPA and PAI-1. Patients with ischaemic stroke classified as cardio-embolic (CEI) showed, compared to other subtypes, significantly higher median plasma levels of TNF-α , IL-6 and IL-1β. Furthermore stroke patients classified as lacunar showed, compared to other subtypes, significantly lower median plasma levels of TNF-α, IL-6 and IL-1β. Multiple linear regression showed a significant association between the Scandinavian Stroke Scale (SSS) score at admission and diagnostic subtype, infarct volume of cardio-embolic strokes and some inflammatory variables. Our findings confirm that cardio-embolic strokes have a worse clinical presentation and produce larger and more disabling strokes than other ischaemic stroke subtypes reporting a possible explanation of higher immuno-inflammatory activation of the acute phase.

Keywords

Cerebral infarct - cerebrovascular accident - cerebrovascular disease - inflammation - risk factors - stroke - cytokines

Full Text

References

References
1 Kimura K, Kazui S, Minematsu K. et al. for the Japan Multicenter Stroke Investigator’s Collaboration. Analysis of 16,922 patients with acute ischaemic stroke and transient ischaemic attack in Japan. A hospital-based prospective registration study. Cerebrovasc Dis 2004; 18: 47-56.
2 Furie KL, Homma S, Kistler JP. Cardiac diseases. In: Stroke: Pathophysiology, Diagnosis, and Management. 4th ed. Churchill Livingstone: New York; 2004. pp. 747-759.
3 Ekdahl CT, Kokaia Z, Lindvall O. Brain inflammation and adult neurogenesis: The dual role of micro-glia. Neuroscience 2008; 158: 1021-1029.
4 Welsh P, Lowe GD, Chalmers J. et al. Associations of proinflammatory cytokines with the risk of recurrent stroke.
5 Stroke 2008; 39: 2226-2230.
6 Lambert MP, Sachais BS, Kowalska MA. Chemokines and thrombogenicity. Thromb Haemost 2007; 97: 722-729.
7 Fateh-Moghadam S, Htun P, Tomandl B. et al. Hyperresponsiveness of platelets in ischaemic stroke. Thromb Haemost 2007; 97: 974-978.
8 Licata G, Tuttolomondo A, Corrao S. et al. Immunoinflammatory activation during the acute phase of lacunar and non-lacunar ischaemic stroke : association with time of onset and diabetic state. Int J Immunopathol Pharmacol 2006; 19: 639-646.
9 Castellanos M, Castillo J, García M. et al. Inflammation-mediated damage in progressing lacunar infarctions. A potential therapeutic target. Stroke 2002; 33: 982-987.
10 Vila N, Castillo J, Davalos A. et al. Proinflamma-tory citokines and early neurological worsening in ischaemic stroke. Stroke 2000; 31: 2325-2329.
11 Sotgiu S, Zanda B, Marchetti B. et al. Inflammatory biomarke rs in blood of patients with acute brain ischaemia. Eur J Neurol 2006; 13: 505-513.
12 Kim JS, Yoon SS, Kim YH. et al. Serial measurement of interleukin-6, transforming growth factor-beta, and S-100 protein in patients with acute stroke. Stroke 1996; 27: 1553-1557.
13 Beamer NB, Coull BM, Clark WM. et al. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann Neurol 1995; 37: 800-805.
14 Perini F, Morra M, Alecci M. et al. Temporal profile of serum anti-inflammatory and pro-inflammatory interleukins in acute ischaemic stroke patients. Neurol Sci 2001; 22: 289-299.
15 Vila N, Castillo J, Davalos A. et al. Proinflamma-tory cytokines and early neurological worsening in ischaemic stroke. Stroke 2000; 31: 2325-2329.
16 Fon EA, Mackey A, Cote R. et al. Hemostatic markers in acute transient ischaemic attacks. Stroke 1994; 25: 282-286.
17 Takano K, Yamaguchi T, Uchida K. Markers of a hypercoagulable state following acute ischaemic stroke. Stroke 1992; 23: 194-198.
18 Sato M, Suzuki A, Nagata K. et al. Increased von Willebrand factor in acute stroke patients with atrial fibrillation. J Stroke Cerebrovasc Dis 2006; 15: 1-7.
19 Clatterbuck RE, Sipos EP. The efficient calculation of neurosurgically relevant volumes from computed tomographic scans using Cavalieri’s direct estimator. Neurosurgery 1997; 40: 339-342.
20 Hatano S. Experience from a multicenter Stroke register; a preliminary report. Bull World Health Organ 1976; 54: 541e53.
21 Adams HP, Bendixen BH, Kappelle J. et al. and the TOAST Investigators.. Classification of subtype of acute ischaemic stroke. Stroke 1993; e24: 358.
22 Chung MK, Martin DO, Sprecher D. et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-2891.
23 Frustaci A, Chimenti C, Bellocci F. et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-1184.
24 Aukrust P, Halvorsen B, Yndestad A. et al. Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol 2008; 1909-1919.
25 Nakase T, Yamazaki T, Ogura N. et al. The impact of inflammation on the pathogenesis and prognosis of ischaemic stroke. J Neurol Sci 2008; 271: 104-109.
26 Smith CJ, Emsley HC, Gavin CM. et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurology 2004; 04: 2-9.
27 Rincon F, Dhamoon M, Moon Y. et al. Stroke location and association with fatal cardiac outcomes. Northern Manhattan Study (NOMAS). Stroke 2008; 39: 2425-2431.
28 Barber M, Wright F, Stott DJ. et al. Predictors of early neurological deterioration after ischaemic stroke: a case-control study. Gerontology 2004; 50: 102-109.
29 Serena J, Rodríguez-Yáñez M, Castellanos M. Deterioration in acute ischaemic stroke as the target for neuroprotection. Cerebrovasc Dis 2006; 21 (Suppl. 02) 80-88.
30 Lubart E, Leibovitz A, Baumoehl Y. et al. Progressing stroke with neurological deterioration in a group of Israeli elderly. Arch Gerontol Geriatr 2005; 41: 95-100.
31 Ferrarese C, Mascarucci P, Zoia C. et al. Increased cytokine release from peripheral blood cells after acute stroke. J Cereb Blood Flow Metab 1999; 19: 1004-1009.
32 Sherman DG. Atrial fibrillation and stroke. J Stroke Cerebrovasc Dis 1997; 06: 165-166.
33 Lin HJ, Wolf PA, Kelly-Hayes M. et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996; 27: 1760-1764.
34 Jorgensen HS, Nakayama H, Reith J. et al. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 1996; 27: 1765-1771.
35 Conway DS, Buggins P, Hughes E. et al. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 2004; 148: 462-466.
36 Chin BS, Blann AD, Gibbs CR. et al. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest 2003; 33: 941-948.
37 Valgimigli M, Ceconi C, Malagutti P. et al. Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. Circulation 2005; 111: 863-870.
38 Lynch JR, Blessing R, White WD. et al. Novel diagnostic test for acute stroke. Stroke 2004; 35: 57-63.
39 Lavados PM, Sacks C, Prina L. et al. Incidence, case-fatality rate, and prognosis of ischaemic stroke subtypes in a predominantly Hispanic-Mestizo population in Iquique, Chile (PISCIS project): a community based incidence study. Lancet Neurol 2007; 06: 140-148.
40 Lindgren A, Norrving B, Rudling O. et al. Comparison of clinical and neuroradiological findings in first-ever stroke: a population based study. Stroke 1994; 25: 1371.
41 Gregersen R, Lambertsen K, Finsen B. Microglia and macrophages are the major source of tumor necrosis factor in permanent middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab 2000; 20: 53-65.